Form 4: Lenz Therapeutics' Chief Medical Officer Granted Stock Options
SEC Form 4 Filing
Marc Odrich, Chief Medical Officer of Lenz Therapeutics, receives stock options according to a Form 4 filing.
Summary
- A Form 4 filing reveals that Marc Odrich, the Chief Medical Officer of Lenz Therapeutics, Inc., was granted stock options on January 9, 2025.
- The stock options allow Odrich to purchase 80,100 shares of common stock at an exercise price of $26.34 per share.
- The options vest over time, with 25% vesting on the one-year anniversary of the Vesting Commencement Date (January 9, 2025), and the remaining shares vesting monthly thereafter.
- Odrich also signed a Power of Attorney, effective January 13, 2025, authorizing certain individuals to act on his behalf in matters related to SEC filings.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive signal.
Positives
- The granting of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
- The vesting schedule incentivizes long-term commitment from the executive.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance, but the stock option grant suggests an expectation of continued service from the Chief Medical Officer.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. This grant aligns with standard compensation practices in the sector.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Regeneron routinely use stock options to incentivize their leadership teams.
- The vesting schedule and exercise price are generally aligned with industry norms, aiming to reward long-term value creation.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning management's interests with the company's long-term success.
- Employees may see this as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 01/09/2025 | Date of earliest transaction (grant of stock options) |
| 01/09/2025 | Vesting Commencement Date for stock options |
| 01/13/2025 | Date of Power of Attorney execution |
| 01/08/2035 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.